ArticleMolecular medicine reports
Identification of signature genes for detecting hedgehog signaling activation in gastric cancer.
Article in Molecular medicine reports. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 4 citations in OpenAlex.
- Hedgehog pathway aberrations and gastric cancer; evaluation of prognostic impact and exploration of therapeutic potentials.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Review
- Identification of signature genes for detecting hedgehog pathway activation in esophageal cancer.Pathology oncology research : POR · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
The aim of this study was to investigate the expression of hedgehog signaling molecules in gastric cancer. In situ hybridization, immunohistochemistry and RT-PCR for hedgehog signaling molecules, smoothened (SMO), suppressor of fused [Su(Fu)], and the target genes hedgehog-interacting protein (HIP) and platelet-derived growth factor receptor α (PDGFRα) were performed in 30 gastric cancer and two gastritis specimens. Using in situ hybridization, SMO expression was detected in 18/30 cancerous specimens (60%) as well as in 1/2 gastritis specimens (50%). Su(Fu) was expressed in 15/30 (50%), HIP in 14/30 (≈47%), and PDGFRα in 6/30 (20%) gastric cancer specimens. Despite the heterogeneous expression pattern, SMO, Su(Fu) and PDGFRα transcripts were highly correlated with the HIP transcript in the 30 gastric cancer specimens (p=0.0006, 0.0003 and 0.0441, respectively). Results from the in situ hybridization were further confirmed by RT-PCR for the expression of all of the genes and by immunohistochemistry for SMO expression. The findings revealed a set of genes for detecting Hh signaling activation in gastric cancer.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.